New Role for the Mitochondrial Peptide Humanin: Protective Agent Against Chemotherapy-Induced Side Effects
Menée sur des lignées cellulaires et à l'aide de modèles murins, cette étude évalue l'intérêt d'un petptide anti-apoptotique (humanine) pour prévenir les effets du bortezomib sur la croissance osseuse
The remarkable advances made over the last several decades in the form of effective therapies that have substantially reduced the mortality from various malignancies, particularly those affecting pediatric patients, has presented the medical community with new challenges of dealing with cancer chemotherapy side effects. Cancer survivors, especially those who were treated for their cancer as children or adolescents, are frequently afflicted with various endocrinopathies, infertility, and growth impairment (1). Current adjuvant therapies that have been approved for dealing with chemotherapy side effects mainly address acute symptoms, such as nausea, and bone marrow renewal. There are multiple cancer drugs that cause damage to the growth plates of growing bones and currently can only be dealt with through later treatment with growth hormone and with variable results (2).
The findings in the article by Eriksson and colleagues in this issue of the Journal (3) show that bortezomib-induced growth failure in mice was almost completely ameliorated by cotreatment with an analog of the mitochondrial-derived peptide humanin, while not interfering with the antitumor effects of bortezomib. Although not approved in children, bortezomib holds …
Journal of the National Cancer Institute , éditorial, 2014